导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.75% | 740/4773 |
| 近一周 | -2.52% | 2450/5462 |
| 近一月 | -3.80% | 1968/5421 |
| 近一季 | -4.39% | 1619/5209 |
| 近半年 | 0.46% | 1156/4920 |
| 近一年 | 14.87% | 712/4366 |
| 近两年 | 92.49% | 663/2954 |
| 近三年 | 62.20% | 412/2253 |
| 成立以来 | 206.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.44% 1276/4961 |
20.31% 1235/5312 |
- - |
- - |
| 2025 | 36.45% 947/4813 |
4.20% 979/3635 |
5.26% 620/4076 |
23.18% 1565/4524 |
1.00% 1610/4813 |
| 2024 | 11.92% 1288/3463 |
-1.38% 1218/2808 |
-2.17% 1145/3014 |
13.49% 2161/3129 |
2.22% 971/3463 |
| 2023 | -5.76% 774/2656 |
5.37% 791/2280 |
-3.55% 825/2385 |
-3.16% 860/2515 |
-4.24% 926/2655 |
| 2022 | -19.75% 890/2207 |
-13.81% 847/1919 |
4.30% 1026/2016 |
-9.28% 264/2113 |
-1.59% 1715/2208 |
| 2021 | 32.16% 60/1822 |
6.17% 98/1255 |
15.39% 225/1330 |
9.28% 138/1466 |
-1.28% 1349/1822 |
| 2020 | 41.37% 293/1250 |
-3.69% 316/1028 |
19.73% 292/1067 |
16.57% 147/1164 |
5.17% 801/1184 |
| 2019 | - - |
- - |
-5.57% 471/788 |
0.83% 453/850 |
8.32% 327/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博道中证500增强A VS. 长安沪深300非周期A(740101) |